

## Message

**From:** Daniel Young [/O=THERANOS ORGANIZATION/OU=FIRST ADMINISTRATIVE GROUP/CN=RECIPIENTS/CN=DYOUNG]  
**Sent:** 2/16/2012 6:22:24 AM  
**To:** Elizabeth Holmes [eholmes@theranos.com]  
**CC:** Sunny Balwani [sbalwani@theranos.com]  
**Subject:** RE: Follow up on data for CMS

The updates to the CMS CPT list are attached. The compiled list actually also includes CPTs that came from customer data sets as well as just the CPTs that are from the latest 2012 CMS list. Column G allows you to filter on CPTs that are included on the latest CMS list (CLAB2012). For the tests on the CMS list, we have also included the CMS national reimbursement limit for your reference.

As you will see from the CPTs from the CLAB2012 list (n=1138), there are n=116 that are currently categorized as "NP", namely "not planned with current technology on Theranos devices at this time".

Below is the "Key" to the categories we assigned for each CPT. "NP" is the only category that is identified as not planned for Theranos devices at this time. There are some tests/procedures that are "LV2" (level 2 codes), and appear to be context dependent (such as emergency procedures/tests). We are still researching these few codes to resolve the implications of these.

Key:

<b>Np</b>	not planned for minilab, i.e. does not map on to existing Theranos device assay technologies
<b>Ncp</b>	no chemistry is associated with the CPT code, but the procedure is covered
<b>Pp</b>	panel, planned for minilab
<b>Sp</b>	single chemistry, planned for minilab
<b>Gp</b>	generic CPT, maps on to multiple chemistries, planned for minilab
<b>Gsp</b>	generic, only in the sense of sample, i.e. chemistry is well defined, but sample could be anything
<b>Sgp</b>	single constituent identified as part of a generic CPT
<b>lv2</b>	level 2 hcpcs code (we need to research more the context of these codes)

Please let me know if you have any questions. Thanks to Chinmay and Swapna for reviewing many of these CPT details.

-Daniel

---

**From:** Elizabeth Holmes  
**Sent:** Wednesday, February 15, 2012 2:31 PM  
**To:** Daniel Young  
**Cc:** Sunny Balwani  
**Subject:** RE: Follow up on data for CMS

Great. Please send out/drop by whenever these are ready. We need to get materials out on this asap.

---

**From:** Daniel Young  
**Sent:** Wednesday, February 15, 2012 11:29 AM  
**To:** Elizabeth Holmes

**Cc:** Sunny Balwani  
**Subject:** RE: Follow up on data for CMS

We have completed the updates we discussed, and I am doing a final review today.

-Daniel

---

**From:** Elizabeth Holmes  
**Sent:** Wednesday, February 15, 2012 9:54 AM  
**To:** Daniel Young  
**Cc:** Sunny Balwani  
**Subject:** Follow up on data for CMS

Do we have this spreadsheet in follow up to our last meeting?

Elizabeth Holmes  
CEO  
Theranos, Inc.

Tel: 650.470.6111  
Fax: 650.838.9804

=====  
**PRIVILEGED AND CONFIDENTIAL COMMUNICATION**

IMPORTANT -- This electronic transmission, and any files transmitted with it are confidential and/or legally privileged information. This information is intended solely for the use of the individual or entity to which they are addressed. Any disclosure, retransmission, reproduction, dissemination or other use of the contents of this information by persons or entities other than the intended recipient is strictly prohibited. If you have received this email in error, please contact us immediately and delete all copies. Please note that any views or opinions presented in this email are solely those of the author and do not necessarily represent those of Theranos, Inc. Finally, before opening or using attachments the recipient should check this email and any attachments for the presence of viruses. Theranos, Inc. accepts no liability for any damage caused by any virus transmitted by this email. Our sole responsibility is limited to resupplying any affected attachments.

Theranos, Inc., 3200 Hillview Avenue, Palo Alto, CA, 94304  
650-838-9292 [www.theranos.com](http://www.theranos.com)

=====

File Produced in Native Format